Chronic lung infections in cystic fibrosis (CF) could be treated more effectively if the effect of antimicrobials on pathogens in situ were known. Here, we compared changes in the microbial community composition and pathogen growth rates in longitudinal studies of CF patients undergoing intravenous antibiotic administration during pulmonary exacerbations. Microbial community composition was measured by NanoString DNA analysis and growth rates were obtained by incubating CF sputum with heavy water and tracing incorporation of deuterium into two different anteiso fatty acids ( a C 15:0 and a C 17:0 ) using gas chromatography-mass spectrometry (GC/MS). Prior to this study, both lipids were thought to be specific for Staphylococcaceae and hence their isotopic enrichment was interpreted as a growth proxy for S. aureus . Our experiments revealed, however, that Prevotella is also a relevant microbial producer of a C 17:0 fatty acid in some CF patients, thus deuterium incorporation into these lipids is better interpreted as a more general pathogen growth rate proxy. Even accounting for a small nonmicrobial background source detected in some patient samples, a C 15:0 fatty acid still appear to be a relatively robust proxy for CF pathogens , revealing a median generation time of~1.5 days, similar to prior observations. Contrary to our expectations, pathogen growth rates remained relatively stable throughout exacerbation treatment. We suggest two best practices for application of stable isotope probing in CF sputum: (1) parallel determination of microbial community composition in CF sputum using cultureindependent tools, and (2) analysis of samples with a minimum a C 15:0 concentration of 0.1 weight percent of saturated fatty acids.
INTRODUCTION
Cystic Fibrosis (CF) is a genetic disease that affects more than 30,000 individuals in North America with a median predicted survival age of 41.6 years (1) . This disease is caused by mutations in the CF transmembrane conductance regulator (CFTR) protein that functions as an apical epithelial chloride channel. Reduced or absent chloride channel function leads to dehydrated, viscous secretions that cause dysfunction in the lungs, pancreas and other organs. As CF progresses, bacteria colonize the lung, resulting in chronic polymicrobial infections and inflammation (2) . These infections are notoriously hard to treat because species, strains within a species, and genomic variants within a strain differ between individuals and discrete regions of the lung; infections become more resistant to drug treatment as the pulmonary disease progresses (3, 4) . Understanding which pathogens are present can inform the choice of appropriate treatment strategies (5) and improve lung function, in tandem with restoration of CFTR activity by CFTR potentiator drugs such as Ivacaftor (6) . Staphylococcus aureus is one of the earliest bacteria detected in infants and children with CF (7) .
The development of chronic polymicrobial infections in the CF lung involves many contributing factors.
S. aureus is the most prevalent bacterium (70.6%) detected on culture in patients with CF in the US (1) .
Over the past decade, the prevalence of methicillinresistant Staphylococcus aureus (MRSA) has increased in CF patients in the United States. Compared to CF patients with methicillinsensitive S. aureus (MSSA) infections, CF patients with MRSA have lower lung function, increased likelihood of hospitalization and lack of responsiveness to antibiotic treatment (8) . Persistent MRSA infection in CF patients between 821 years is associated with more rapid lung function decline (9) .
CF patients experience episodes of acute worsening of respiratory symptoms called pulmonary exacerbations. Pulmonary exacerbations are treated with antibiotics and airway clearance therapies (10) .
For decades, antibiotics have been the cornerstone of CF care and in recent years, there has been a clinical focus on the aggressive management of pulmonary exacerbations because 25% of CF patients do not recover their baseline lung function after intravenous antibiotic treatment for a pulmonary exacerbation (11) . A higher risk of failing to recover to baseline lung function was associated with several factors, including persistent infection with P. aeruginosa or MRSA (11) .
A largely unresolved question is how quickly CF pathogens proliferate in the lung during antibiotic therapy (12) (13) (14) (15) . It is conceivable that the ability of infections to persist in the lung is connected in intricate ways to slow growth rates. Slow bacterial growth, for example in biofilms, can be beneficial for survival partly because many drugs have their greatest effect on rapidly dividing cells (16) .
Nevertheless, for a microbial population to persist in the lung, a certain amount of growth is necessary to counteract loss of cells due to attack by the immune system or mucociliary clearance. As chronic infections have highly complex and heterogeneous composition, it is challenging to determine in situ growth rates of CF pathogens . Recently, two advances in microbial ecology have enabled to measure microbial growth rates in situ . The first is based on DNA sequencing and exploits the observation that growing cells yield more sequencing reads at genomic regions near the origin of replication (17, 18) . This difference between nongrowing and rapidly growing cells is relatively small (a maximum 2fold increase when assuming duplication of origin of replication in growing cells). To derive quantitative information from this signal, metagenomic data must have high sequence coverage, assumptions must be made about chromosome copy number in growing cells, and care must be taken to avoid biases introduced by preferential DNA sequencing from certain members of the population. The second approach uses isotopic labeling and mass spectrometry to quantify the incorporation of isotopes into biomass, which provides a more direct measurement of anabolic activity (14, 19) . Stable isotope probing requires incubation of the sample with isotopic label and relies on the identification of diagnostic metabolites. Because the natural abundance of rare isotopes such as deuterium is small and the number of metabolite molecules per cell is large, the sensitive detection of isotope incorporation into metabolites by mass spectrometry can have a greater dynamic range than DNA sequencing. Thus, stableisotope probing may be better suited for studies that attempt to gain growth information for microbes in a sample where microbes would be expected to be growing slowly and the DNA of the target organism(s) might only make up only a small portion of the total DNA. While DNA sequencing and stable isotope probing provide new opportunities to study in situ growth rates, both methods provide information by analyzing bulk extracts and cannot resolve spatial organization and heterogeneity (14) , though techniques are emerging that permit microbial metabolic activity to be measured at the singlecell level (20) (21) (22) .
Utilizing a bulk stableisotope labeling approach, we previously attempted to quantify S. aureus growth rates in CF sputum; we found that its growth rate was slowest in acutely sick patients, despite extensive growth rate heterogeneity at the singlecell level (14) . Freshly expectorated sputum was incubated with heavy water (D 2 O) and incorporation of deuterium into diagnostic fatty acids was measured. These fatty acids, anteiso C15:0 ( a C 15:0 ) and anteiso C17:0 ( a C 17:0 ), are the dominant fatty acids of S. aureus and their biosynthesis rate was used as a proxy for growth of the pathogen. The two main findings of the previous study (14) were: (1) S. aureus had a median in situ generation time of~2 days, far slower than previous estimates of CF pathogen growth rates, and (2) growth rates were slowest in patients during early treatment of pulmonary exacerbations ( i.e. first few days). The slow growth rates we measured support the hypothesis that S. aureus populations experience environmental constraints within the lung, which could facilitate tolerance to conventional antibiotics. Based on the observed crosssectional growth trends (14) , we hypothesized that during early hospitalization, treatment with antiStaphylococcal antibiotics may have suppressed S. aureus growth rates but as other members of the microbial community also succumbed to antibiotic treatment, S. aureus could occupy these abandoned niches and grow more quickly.
This study was designed to test this hypothesis by performing a longitudinal study. We correlated changes of microbial community composition with S. aureus growth rate in a cohort of CF patients that were treated with intravenous antibiotics due to pulmonary exacerbations. Our results did not support our hypothesis, but lead to important refinements in our approach to measuring in situ growth rates in clinical samples. , the remaining longitudinal series were collected from patients with mild to moderate lung disease. All patients recovered to their spirometric baseline forced expiratory volume in one second (FEV1%) following treatment. Clinical and demographic information for study participants is summarized in Table 1 (see   also Table S1 and S2).
RESULTS

We
The individual time series revealed dramatic changes in the microbial populations based on counting ribosomal RNA within total RNA extracted from sputum using NanoString technology ( Figure   1 ). Though for this study we specifically recruited CF patients with S. aureus infections on the basis of clinical cultures, polymicrobial infections were the norm, as expected (23) . In three patients, S. aureus was the most abundant member of the microbial community at the beginning of treatment (Patient 1, 2, 3). In some patients Prevotella melaninogenica (Patient 4, 5) or Pseudomonas aeruginosa (Patient 6, 7)
were most abundant. For Patient 7, P. aeruginosa accounted for almost all (>96%) of NanoString counts, while S. aureus was detected only at the beginning of hospitalization (0.4% abundance). During treatment, the relative abundance of S. aureus decreased in most patients as assessed by rRNA levels.
Patient 1, however, who had severe lung disease, showed a varied response. Based on total NanoString counts we can infer microbial population size ( Figure 1 ) (24) . Several patients showed a large decrease in microbial population size throughout their hospital stay (Patients 2, 3, 5 and 6), whereas in Patient 1, microbial population size did not decrease, and even increased in Patients 4 and 7. These time series illustrate that CF microbial infections change and mature differently in individuals during antimicrobial therapy. Accordingly, we might expect that differential microbial growth activities during drug treatment in any given patient would correlate with the rise or fall of particular members of the microbial community. To determine whether this was the case, we focused on measuring the growth activity of S. aureus by tracking anteiso fatty acids previously thought to be diagnostic for this bacterium in the context of CF microbial communities, comparing its specific growth rates to changes in the microbial community composition ( Figure 2 ). Although S.aureus was detected in initial sputum cultures of all patients included in the longitudinal study, our analysis of microbial populations showed that Patient 7 contained almost exclusively P. aeruginosa . This bacterium does not produce anteiso fatty acids so we did not expect to detect a C 15:0 and a C 17:0 analytes in samples from Patient 7. Nevertheless, a C 17:0 occurred at abundances >0.15% (wt% of saturated fatty acids), which is similar to the levels in sputum from patients that had dominant S. aureus infections (e.g., Patient 1). For comparison, we analyzed sputum samples from three CF patients whose clinical data did not indicate presence of S. aureus . Two of these controls also contained more than 0.15% a C 17:0 in two samples. Interestingly, a C 15:0 was detected at lower abundances (<0.05%) in Patient 7 and the three controls. This suggested that sources other than S. aureus can contribute anteiso fatty acids, especially a C 17:0 , in expectorated sputum.
Whether non Staphylococcal sources of anteiso fatty acids were sufficiently abundant to affect the interpretation of our D 2 Olabeling experiments became the next question. Our prior work had taught us that Stenotrophomonas species can also produce anteiso fatty acids and can occur in CF sputum (14) .
In some samples from Patient 5, Stenotrophomonas maltophilia constituted the majority of microorganisms. The fatty acid analysis of these sputum samples also revealed an increased amount of iso C 15:0 , which had been observed for the pure strain (14) . In all other patients, S. maltophilia occurred at low abundances (<1%), too low to account for the high levels of a C 17:0 we measured. For example, in anteiso fatty acids but it was not previously recognized as a relevant source of anteiso fatty acids in CF sputum (14, 25) . P. melaninogenica is an anaerobe and part of the oral flora. It was isolated from CF sputum and in bronchoalveolar lavage fluid from infants with CF (26, 27) , yet the clinical significance of Prevotella in CF lung disease is still debated (28) .
Sputum from Patient 7 had elevated a C 17:0 but did not contain Prevotella (Figure 2 ). This raised the new concern that perhaps additional input of anteiso fatty acids might emanate from the human host itself. Anteiso fatty acids are rare in human tissues but can accumulate in skin and fat cells (29) . Might human cells, such as neutrophils and epithelial cells, contribute to the anteiso fatty acids pool in expectorated CF sputum? To answer this question, we analyzed the fatty acid composition of two human cell lines ( Table 2 ). CF bronchial epithelial cells (CFBE) and polymorphonuclear neutrophils (PMN) indeed contained anteiso fatty acids on the order of 0.1 wt% of total fatty acids. It is possible that some of these anteiso lipids in cell cultures originate from the growth substrate. Fetal bovine serum (FBS), the only component of the growth medium that contains lipids, contained a similar percentage of anteiso fatty acids and hence diet could also be a contributing factor. For humans, dietary intake of anteiso fatty acids in the United States is largely via milk and meat products (30) . We concluded that an additional source of anteiso fatty acids in expectorated sputum likely stems from human cells or dietary intake. The impact of this contribution on the interpretation of D 2 Olabeling experiments will depend on the relative contribution of human cells to the pool of anteiso fatty acids in a given sample. when deuterium incorporation is interpreted without taking microbial abundance and community composition into account (Figure 3 ). For example, the second time series for Patient 1 (1 #2), who had two hospitalizations one month apart, showed a slower growth rate during hospitalization followed by a rebound increase in growth rate. This patient had severe lung disease (baseline FEV1 34%) requiring noninvasive ventilation during sleep and treatment for chronic airway P.aeruginosa colonization with cycled nebulized tobramycin. However, a similar growth rate trend was not observed in the same patient during the first hospitalization (Patient 1 #1) and in other patients. It is possible that these discrepancies could be due to stochastic differences in sputum composition with respect to the proportion of human:microbial cells at these different time points. Whether or not this was the case, the majority of our longitudinal time series did not show an obvious connection between the duration of intravenous antibiotic treatment and deuterium labeling of anteiso fatty acids.
Most samples in our longitudinal dataset contain a C 15:0 at concentrations that are significantly higher (10 to 50fold) than those of Patient 7, in which S. aureus is absent ( Figure 2 ). Accordingly, a C 15:0 in these samples is likely providing information about the growth of other CFassociated microbes that produce a C 15:0 , namely P. melaninogenica and S. maltophilia . Whether isotope incorporation yields reliable growth rates for any pathogen also depends on the labeling rates of anteiso fatty acids from nonmicrobial origins. Nonmicrobial sources mainly appear to contribute a C 17:0 , which in CF sputum generally shows slower label incorporation than a C 15:0 (14) . Accordingly, contributions of nonmicrobial anteiso fatty acids tend to decrease growth rate estimates.
To better constrain how nonmicrobial anteiso fatty acids might affect our ability to infer microbial growth rates, we analyzed their potential impact using modeling. To a first approximation, we assume the pool of anteiso fatty acids is a mixture of two end members at the beginning of the labeling experiment: a portion of biosynthetically active microbial lipids ( x ) and a portion of inactive dietary 
The effect of nonmicrobial sources of anteiso fatty acids on bacterial growth rate estimates from this basic model is shown in Figure 4A . For example, if the microbes have an actual generation time of 2 days and 90% of the anteiso fatty acids originate are microbial origin and the remaining 10 % dietary, the apparent generation time after 1 hour of incubation would be 2.2 days, i.e. only slightly slower than the actual doubling every 2 days.
We can extend this basic model to include scenarios in which nonbacterial fatty acids can become isotopically labeled, e.g. due to de novo biosynthesis in human cells. If we assume a constant generation time GT b for the bacterial fraction ( x ) and GT n for the nonbacterial fraction ( 1x ), the apparent generation time y is given by: y = t / log 2 [x*2 t/GTb + (1 x) * 2 t/GTn ] Eq. 1.2 Figure 4B shows the effect of nonbacterial growth with a generation time of 20 days ( GT n ), which is on the order of generation times measured for a C 17:0 in samples from Patient 7 (presumed to be nonbacterial in origin). In this extended model, the nonbacterial fatty acids have a relatively slow but nonzero isotope incorporation, as a result the deviations between actual and apparent microbial growth rates tend to be smaller than the simpler model.
This sensitivity analysis suggests that a C 15:0 can be interpreted as a robust proxy for bacterial growth in CF infections provided most of the analyte originates from bacteria. In sputum from Patient 7, a C 15:0 did not derive from any known microbial sources and was detected at a mean concentration of 0.025 wt%. Using 4fold this value (0.1 wt%) as a threshold, we filtered our longitudinal data to identify samples for which microbial growth rates in sputum could be obtained reliably from deuterium labeling of a C 15:0 . The median growth rates estimated for these 23 samples is 1.9 days, which represents a mixture of growth rates for all three anteiso fatty acid producing microbial strains ( Table 3) Much of the variability we observe in deuterium labeling data was eliminated when focusing our analysis on samples that had high levels of a C15:0. These samples generally yielded generation times between 0.5 and 2.5 days, with a median of 1.9 days (Table 3 ). Samples dominated by S. aureus (>50%) had a median generation time of 1.5 days. Overall, these estimates for generation times are in the range measured for a C 15:0 in our previous dataset (14) . Because isotopic labeling only provides an average growth estimation for the microbial population, we cannot exclude the possibility that a subpopulation of cells grows significantly slower or faster than with the median generation times we observe. To resolve heterogeneity at this level, singlecell growth rate visualization are necessary (21, 22) . allow confident estimation of pathogen growth rates (Table 4 ), we find that growth rate estimates generally remained stable during treatment. We note that samples with low levels of aC 15:0 producing microorganisms do not yield reliable pathogen growth estimates. However, samples containing high levels of a C 15:0 and low deuterium incorporation values likely indicate that an antibiotic is inhibiting pathogen growth (Patient 3; day 4). In sum, stable isotope probing in combination with community analysis did not support our previous hypothesis that the S. aureus population undergoes niche expansion during antibiotic treatment during an exacerbation. To the contrary, our NanoString data showed that all patients had lower relative abundance of S. aureus at the end of treatment compared to the beginning.
In conclusion, stable isotope probing is likely to be most useful in tracking pathogen growth dynamics in response to antibiotic treatment early during pulmonary exacerbations, when pathogenic load is high. With future development, rapid analysis of incubations of CF sputum with different drugs may even help identify the most promising treatment options. Currently, we are developing a method to quantify deuterium label in intact lipids with LC/MS (31) . This approach promises to increase the utility of stable isotope probing to assess growth of diverse pathogens. The medical records of enrolled subjects were reviewed for age, gender, body mass index, CFTR mutations, duration of hospitalization, results of CF sputum culture, mycobacterial culture, antibiotics used and results of pulmonary function tests. This information is presented in Table 1 , S1 and S2. RNA isolation and analysis . For sputum community profiles, RNA was prepared and analyzed as described by Grahl et al. (24) . Measurements were made using a NanoString nCounter (NanoString Technologies) (32) . We used the customdesigned Nanostring CodeSet described in (24) , which enables the simultaneous detection of ribosomal RNA for 38 clinically relevant CFrelated bacterial and fungal species or genera. Raw counts were corrected by subtracting 5 times the maximum count for internal negative controls (24) . Deuterium enrichments were quantified in replicates on a DELTA + XP (Thermo Fisher Scientific) by GC pyrolysis isotoperatio mass spectrometry (GC/P/IRMS) as in Kopf et al. (14) with the following optimization. The GC program was adjusted for shorter run time and better peak separation of target analytes, a C 15:0 and a C 17:0 . The GC oven was held at 80 °C for 0.5 min, temperature then was increased at 30°C/min to 170 °C, held at 170°C for 45 min, increased again at 30°C/min to 190 °C, followed by a final increase of 30°C/min to 320°C (held for 10 min 
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